Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Recruiting

Phase 3

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Sponsor:

Amgen

Code:

NCT06700343

Conditions

Relapsing-remitting Multiple Sclerosis (RRMS)

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ocrelizumab (US)

Ocrelizumab (EU)

ABP 692

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-29. This information was provided to ClinicalTrials.gov by Amgen on 2025-03-28.